ARTICLE
18 February 2020

Analysis: Navigating US Federal And State Rules During The Novel Coronavirus Public Health Emergency

The novel coronavirus (2019-nCoV, also known as "SARS-CoV-2") has been declared a public health emergency (PHE) by the U.S. Department of Health and Human Services (HHS).
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

The novel coronavirus (2019-nCoV, also known as "SARS-CoV-2") has been declared a public health emergency (PHE) by the U.S. Department of Health and Human Services (HHS). This designation authorizes HHS to direct funding to: (1) enable the dissemination of information about the virus; (2) encourage research and development of diagnostic and treatment techniques; (3) improve screening and detection efforts; and (4) support state and local governments in virus control efforts.

Reed Smith has prepared a client alert that provides an overview of government PHE regulatory authorities and analyzes federal and state regulations impacting health care providers, suppliers, and facilities when a federal PHE has been declared or an infectious disease outbreak occurs under state law. Among other things, the client alert addresses: Emergency Medical Treatment and Active Labor Act (EMTALA), Stark Law, and other federal waivers; state law police powers, including quarantine; relevant rules for disclosure of personal health information; FDA emergency authorization for coronavirus diagnostic test; and supply chain concerns and 340B pricing implications.

This article is presented for informational purposes only and is not intended to constitute legal advice.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More